ReviewClinical endocrinology2025
Glucagonoma and Glucagonoma Syndrome: An Updated Review.
Review in Clinical endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- From companion animals to patients: interspecies lessons in neuroendocrine oncology.Frontiers in veterinary science · 2026Review
- Study on Autophagy Death of Alpha TC1 Clone 6 (αTC1-6) Cells Induced by Trametenolic Acid Through PI3K/AKT Pathway.Current issues in molecular biology · 2025Article
- Diagnosis and Management of Functional Pancreatic Neuroendocrine Tumors in Children-A Systematic Review.Diagnostics (Basel, Switzerland) · 2025Review
- Recent Updates on Diabetes and Bone.International journal of molecular sciences · 2025Review
- Exceptional Response of Necrolytic Migratory Erythema to Octreotide in a Patient with Glucagonoma: A Case Report and Scoping Review.Case reports in dermatologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGlucagonoma is a rare well-differentiated slowly proliferating pancreatic neuroendocrine tumour, characterized by several manifestations including necrolytic migratory erythema, weight loss, diabetes and anaemia.
aimThe purpose of the current review was to acknowledge literature about this rare tumour discerning the clinical features, diagnosis, treatment and prognosis of glucagonoma by comparing three different periods.
resultsA study published by Song reviewed 216 cases from studies published between 1999 and 2016, making a comparison with 407 cases reported before 1998 by Soga and Yakuwa. The current review consisted of 86 cases reported in studies published in and after 2017: 40 males and 46 females, with an average age of 48.2 years. The male-to-female ratio was 0.87. The rate of typical clinical findings was as follows: NME, 93.2% (69/74); DM, 70.3% (50/74); weight loss, 62.2% (46/74); anaemia, 44.6% (33/74); glossitis or stomatitis or cheilitis, 31.1% (23/74). A total of 85 cases reported the location of the tumour as the pancreas and 38.8% of these cases involved the tail of the pancreas. The average tumour size was 4.6 cm in patients between 2017 and 2024. Metastasis was detected in 52.3% of patients (45/86). The comparison with previous series highlighted an earlier age of diagnosis of glucagonoma and a higher rate of NME, consistent with a higher diagnostic accuracy.
conclusionsGlucagonoma is a rare pathology, with peculiar characteristics that need to be acknowledged to achieve a timely diagnosis and finally improve patient prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.